Breast cancer is one of the most common types of cancer found in women worldwide. However, breast cancer does not always show obvious symptoms in the early stages. Hence, companies in the breast cancer diagnostics market are increasing their R&D in AI technologies to identify unmet patient needs. For instance, Paragon Biosciences LLC announced the launch of its seventh portfolio company Qlarity Imaging LLC, to gain FDA clearance for their AI system used for breast cancer diagnostics in radiology.
Companies in the market are harnessing the advantages of AI to improve medical outcomes. The AI technology is being increasingly used in additional image modalities with the goal of lowering costs for hospitals as well as payers. Companies in the market for breast cancer diagnostics are directing their investments in developing AI systems with intuitive displays and machine learning (ML).
To know the scope of our report Get a Sample on Breast Cancer Diagnostics Market
Most types of breast cancer are treatable and survival rates are high for patients that detect cancer at an early stage. Hence, researchers in the market for breast cancer diagnostics are increasing their focus in novel methods of blood screening that are reinventing techniques for early detection of breast cancer. For instance, researchers from the University of Nottingham are innovating in new blood screening methods that can help detect breast cancer years before it gets severe. Such discoveries are bolstering market growth, as the breast cancer diagnostics market is expected to reach a revenue of ~US$ 9 Bn by the end of 2027. Moreover, molecular testing is anticipated for exponential growth during the forecast period.
On the other hand, researchers are examining antigens and auto-antibodies to determine the presence of a tumor. Tumor-associated antigens (TAAs) are considered as a reliable indicator of breast cancer. Thus, companies in the market should collaborate with researchers to advance in clinical studies.
Get a glimpse of the in-depth analysis through our Report Brochure
Nanotechnology holds promising potential for early detection of breast cancer. This technology is being highly publicized for its high sensitivity, specificity, and multiplexed measurement capacity in the breast cancer diagnostics market. However, translation of nanotechnology-based diagnostic methods into routine clinical applications poses as a challenge for healthcare providers.
The breast cancer diagnostics industry is consolidated with three major players accounting for ~66% of the global market share. This indicates that companies are increasing their research efforts in new diagnostic methods such as nanotechnology and deep learning to improve clinical numbers. However, the reliability of nanotechnology-based cancer diagnosis in regular clinical practices is still at the nascent stage in the market for breast cancer diagnostics. Moreover, high costs associated with the long-term storage of nanoprobes that are highly sensitive is another barrier for market growth. Hence, companies in the market for breast cancer diagnostics are simplifying the synthesis steps and nanoprobe functionalization and are increasing R&D to launch cost-efficient ways of introducing nanotechnology-based diagnosis in clinical practices.
Automated breast cancer diagnostics based on ML algorithms are bringing about a change in the market landscape. Soft computing techniques are being increasingly used to produce accurate and faster diagnosis of breast cancer amongst patients. Hence, healthcare companies in the breast cancer diagnostics market are collaborating with researchers to combine imaging techniques with ML algorithms to increase diagnosis accuracy. Preprocessing, feature extraction, and classification are becoming the key focus points for healthcare companies in order to advance in ML-based imaging techniques.
Several data mining and ML techniques are being used to facilitate careful interpretation and analysis of peripheral areas of the patient. As such, feature extraction plays a pivotal role in breast cancer detection using ML techniques. Such novel techniques are helping practitioners in the market to distinguish between benign and malignant tumors. Transform-based texture analysis techniques are being facilitated to convert the image into new analysis studies using spatial frequency properties.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
AI-assisted technologies have become the frontrunner for innovations in the breast cancer diagnostics market. Thus, the market is expected to expand at a favorable CAGR of ~7% during the forecast period. Precision medicines and personalized therapies are helping to improve clinical numbers. Since ‘cancer’ is commonly associated as an ‘expensive disease’, healthcare companies are increasing their R&S activities to boost the availability of affordable tests and treatments.
ML techniques are gaining prominence in mammographic imaging of regions of interest (ROIs). However, there is a need for more confined approach toward the detection of cancerous lesions in conventional ML studies. Hence, companies should increase focus in architecture distortion and the detection of bilateral asymmetry to innovate in mammographic imaging.
Breast Cancer Diagnostics Market – Segmentation
|
Technique |
Imaging
Tissue Biopsy Tests Molecular Testing |
|
Cancer Type |
Ductal Carcinoma In Situ (DCIS) Invasive Breast Cancer
|
|
End User |
Hospitals & Ambulatory Surgery Centers Diagnostic Laboratories Research & Academic Institutes |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
The market to reach valuation of ~US$ 9 Bn by 2027
The market is expected to expand at a favorable CAGR of ~7% during 2019 - 2027
The market is driven by high prevalence and increase in incidence rate of breast cancer across the globe
North America accounted for a major share of the market in 2018 and the trend is projected to continue during the forecast period
Key players in the market include Abbott Laboratories, Koninklijke Philips N.V., C. R. Bard, Inc., F. Hoffmann-La Roche Ltd., Fujifilm Holding Corporation, Leica Biosystems Nussloch GmbH
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Breast Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Breast Cancer Diagnostics Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Breast Cancer Diagnostics Market Analysis and Forecast, 2018–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Breast Cancer Epidemiology, by Key Countries/Region
5.3. Breast Cancer Epidemiology
6. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Technique
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technique, 2018–2028
6.3.1. Imaging
6.3.1.1. Mammography
6.3.1.1.1. Analog Mammography
6.3.1.1.2. Digital Mammography
6.3.1.1.3. Breast Ultrasound System
6.3.1.1.4. MRI Scan
6.3.1.1.5. PET/CT Scan
6.3.2. Tissue Biopsy Tests
6.3.3. Molecular Testing
6.4. Market Attractiveness Analysis, by Technique
7. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Cancer Type, 2018–2028
7.3.1. Ductal Carcinoma In Situ (DCIS)
7.3.2. Invasive Breast Cancer
7.3.2.1. Invasive Ductal Carcinoma
7.3.2.2. Invasive Lobular Carcinoma
7.3.2.3. Metastatic Breast Cancer
7.3.2.4. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Breast Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2018–2028
8.3.1. Hospitals & Ambulatory Surgery Center
8.3.2. Diagnostic Laboratories
8.3.3. Research & Academic Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Global Breast Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Technique, 2018–2028
10.3.1. Imaging
10.3.1.1. Mammography
10.3.1.1.1. Analog Mammography
10.3.1.1.2. Digital Mammography
10.3.1.2. PET/CT Scan
10.3.2. Tissue Biopsy Tests
10.3.3. Molecular Testing
10.4. Market Value Forecast, by Cancer Type, 2018–2028
10.4.1. Ductal Carcinoma In Situ (DCIS)
10.4.2. Invasive Breast Cancer
10.4.2.1. Invasive Ductal Carcinoma
10.4.2.2. Invasive Lobular Carcinoma
10.4.2.3. Metastatic Breast Cancer
10.4.2.4. Others
10.5. Market Value Forecast, by End-user, 2018–2028
10.5.1. Hospitals & Ambulatory Surgery Center
10.5.2. Diagnostic Laboratories
10.5.3. Research & Academic Institutes
10.6. Market Value Forecast, by Country, 2018–2028
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Technique
10.7.2. By Cancer Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Global Breast Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Technique, 2018–2028
11.3.1. Imaging
11.3.1.1. Mammography
11.3.1.1.1. Analog Mammography
11.3.1.1.2. Digital Mammography
11.3.1.2. PET/CT Scan
11.3.2. Tissue Biopsy Tests
11.3.3. Molecular Testing
11.4. Market Value Forecast, by Cancer Type, 2018–2028
11.4.1. Ductal Carcinoma In Situ (DCIS)
11.4.2. Invasive Breast Cancer
11.4.2.1. Invasive Ductal Carcinoma
11.4.2.2. Invasive Lobular Carcinoma
11.4.2.3. Metastatic Breast Cancer
11.4.2.4. Others
11.5. Market Value Forecast, by End-user, 2018–2028
11.5.1. Hospitals & Ambulatory Surgery Centers
11.5.2. Diagnostic Laboratories
11.5.3. Research & Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2018–2028
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Technique
11.7.2. By Cancer Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Global Breast Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Technique, 2018–2028
12.3.1. Imaging
12.3.1.1. Mammography
12.3.1.1.1. Analog Mammography
12.3.1.1.2. Digital Mammography
12.3.1.2. PET/CT Scan
12.3.2. Tissue Biopsy Tests
12.3.3. Molecular Testing
12.4. Market Value Forecast, by Cancer Type, 2018–2028
12.4.1. Ductal Carcinoma In Situ (DCIS)
12.4.2. Invasive Breast Cancer
12.4.2.1. Invasive Ductal Carcinoma
12.4.2.2. Invasive Lobular Carcinoma
12.4.2.3. Metastatic Breast Cancer
12.4.2.4. Others
12.5. Market Value Forecast, by End-user, 2018–2028
12.5.1. Hospitals & Ambulatory Surgery Centers
12.5.2. Diagnostic Laboratories
12.5.3. Research & Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2018–2028
12.6.1. China
12.6.2. India
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Technique
12.7.2. By Cancer Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Global Breast Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Technique, 2018–2028
13.3.1. Imaging
13.3.1.1. Mammography
13.3.1.1.1. Analog Mammography
13.3.1.1.2. Digital Mammography
13.3.1.2. PET/CT Scan
13.3.2. Tissue Biopsy Tests
13.3.3. Molecular Testing
13.4. Market Value Forecast, by Cancer Type, 2018–2028
13.4.1. Ductal Carcinoma In Situ (DCIS)
13.4.2. Invasive Breast Cancer
13.4.2.1. Invasive Ductal Carcinoma
13.4.2.2. Invasive Lobular Carcinoma
13.4.2.3. Metastatic Breast Cancer
13.4.2.4. Others
13.5. Market Value Forecast, by End-user, 2018–2028
13.5.1. Hospitals & Ambulatory Surgery Centers
13.5.2. Diagnostic Laboratories
13.5.3. Research & Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2018–2028
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Technique
13.7.2. By Cancer Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East and Africa Global Breast Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Technique, 2018–2028
14.3.1. Imaging
14.3.1.1. Mammography
14.3.1.1.1. Analog Mammography
14.3.1.1.2. Digital Mammography
14.3.1.2. PET/CT Scan
14.3.2. Tissue Biopsy Tests
14.3.3. Molecular Testing
14.4. Market Value Forecast, by Cancer Type, 2018–2028
14.4.1. Ductal Carcinoma In Situ (DCIS)
14.4.2. Invasive Breast Cancer
14.4.2.1. Invasive Ductal Carcinoma
14.4.2.2. Invasive Lobular Carcinoma
14.4.2.3. Metastatic Breast Cancer
14.4.2.4. Others
14.5. Market Value Forecast, by End-user, 2018–2028
14.5.1. Hospitals & Ambulatory Surgery Centers
14.5.2. Diagnostic Laboratories
14.5.3. Research & Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2018–2028
14.6.1. GCC
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Technique
14.7.2. By Cancer Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company, 2018
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.1.2. Product Portfolio
15.3.1.1.3. SWOT Analysis
15.3.1.1.4. Strategic Overview
15.3.2. GE Healthcare (General Electric Company)
15.3.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.1.2. Product Portfolio
15.3.2.1.3. SWOT Analysis
15.3.2.1.4. Strategic Overview
15.3.3. Koninklijke Philips N.V.
15.3.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.1.2. Product Portfolio
15.3.3.1.3. SWOT Analysis
15.3.3.1.4. Strategic Overview
15.3.4. Hologic, Inc.
15.3.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.1.2. Product Portfolio
15.3.4.1.3. SWOT Analysis
15.3.4.1.4. Strategic Overview
15.3.5. C. R. Bard, Inc. (Becton, Dickinson and Company)
15.3.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.1.2. Product Portfolio
15.3.5.1.3. SWOT Analysis
15.3.5.1.4. Strategic Overview
15.3.6. Siemens Healthineers (Siemens AG)
15.3.6.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.1.2. Product Portfolio
15.3.6.1.3. SWOT Analysis
15.3.6.1.4. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.1.2. Product Portfolio
15.3.7.1.3. SWOT Analysis
15.3.7.1.4. Strategic Overview
15.3.8. Fujifilm Holding Corporation
15.3.8.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.1.2. Product Portfolio
15.3.8.1.3. SWOT Analysis
15.3.8.1.4. Strategic Overview
15.3.9. Leica Biosystems Nussloch GmbH (Danaher)
15.3.9.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.1.2. Product Portfolio
15.3.9.1.3. SWOT Analysis
15.3.9.1.4. Strategic Overview
15.3.10. bioTheranostics, Inc.
15.3.10.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.1.2. Product Portfolio
15.3.10.1.3. SWOT Analysis
15.3.10.1.4. Strategic Overview
15.3.11. Myriad Genetics, Inc.
15.3.11.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.1.2. Product Portfolio
15.3.11.1.3. SWOT Analysis
15.3.11.1.4. Strategic Overview
List of Tables
Table 01: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 02: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 03: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 04: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 05: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 06: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 07: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 10: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 11: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 12: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 13: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 14: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 15: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 16: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 17: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 18: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 19: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 20: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 21: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 22: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 23: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 24: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 25: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 26: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 27: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 28: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 29: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 30: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 31: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 32: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 33: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 34: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 35: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 36: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 37: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 38: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 39: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 40: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 41: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 42: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
List of Figures
Figure 01 Global Breast Cancer Diagnostics Market Value (US$ Mn), 2018 and 2027
Figure 02 Global Breast Cancer Diagnostics Market, Market Snapshot
Figure 03: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 04: Global Breast Cancer Diagnostics Market Value Share, by Technique, 2018
Figure 05: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018
Figure 06: Global Breast Cancer Diagnostics Market Value Share, by End-user, 2018
Figure 07: Global Breast Cancer Diagnostics Market Value Share, by Region, 2018
Figure 08: Global Breast Cancer Diagnostics Market Value Share, by Technique, 2018 and 2027
Figure 09: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 10: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Imaging, 2017–2027
Figure 11: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Tissue Biopsy Tests, 2017–2027
Figure 12: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Molecular Testing, 2017–2027
Figure 13: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 14: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 15: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ductal Carcinoma In Situ (DCIS), 2017–2027
Figure 16: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Invasive Breast Cancer, 2017–2027
Figure 17: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 18: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 19: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals & Ambulatory Surgery Center, 2017–2027
Figure 20: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Laboratories, 2017–2027
Figure 21: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Research & Academic Institutes, 2017–2027
Figure 22: Global Breast Cancer Diagnostics Market Value Share, by Region, 2018 and 2027
Figure 23: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Region, 2019–2027
Figure 24: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 25: North America Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 26: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027
Figure 27: North America Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027
Figure 28: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 29: North America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 30: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 31: North America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 32: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 33: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 34: Europe Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 35: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027
Figure 36: Europe Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027
Figure 37: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 38: Europe Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 39: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 40: Europe Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 41: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 42: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 43: Asia Pacific Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 44: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027
Figure 45: Asia Pacific Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027
Figure 46: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 47: Asia Pacific Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 48: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 49: Asia Pacific Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 50: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 51: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 52: Latin America Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 53: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027
Figure 54: Latin America Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027
Figure 55: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 56: Latin America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 57: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 58: Latin America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 59: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 60: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027
Figure 61: Middle East & Africa Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027
Figure 62: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027
Figure 63: Middle East & Africa Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027
Figure 64: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027
Figure 65: Middle East & Africa Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 66: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 67: Middle East & Africa Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027
Figure 68: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027
Figure 69: Global Breast Cancer Diagnostics Market Share Analysis, by Company, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Breast Cancer Diagnostics Market
*86 figures and 60 tables includes